Melanotan-1 · Research brief
Melanotan-1 Results After 1 Week — What to Expect
Short answer
Most people expect visible tan lines after seven days on Melanotan-1 . What they actually get is a baseline establishment phase that looks nearly identical to where they started. No dramatic color shift, no Instagram-ready glow, just faint signs of melanin synthesis beginning at the cellular level.
Key takeaways
- Melanotan-1 results after 1 week show minimal visible tanning because eumelanin requires 10–21 days of cumulative synthesis and keratinocyte transfer to become perceptible.
- Tyrosinase activity peaks within 48–96 hours of initial dosing, but enzymatic upregulation doesn't translate to visible pigment until melanin accumulates in the epidermis.
- Subjects at 0.5mg daily typically notice slight mole or freckle darkening by day seven. A reliable marker that MC1R activation is occurring even when baseline skin tone remains unchanged.
- UV exposure during week one accelerates melanin transfer and can advance visible tanning onset by 7–10 days compared to peptide-only protocols.
- Side effects (nausea, flushing, appetite suppression) are most common in the first 72 hours and correlate with dose. 1mg daily produces faster melanogenesis but 40–60% discontinuation rates in peptide-naive subjects.
Most people expect visible tan lines after seven days on Melanotan-1. What they actually get is a baseline establishment phase that looks nearly identical to where they started. No dramatic color shift, no Instagram-ready glow, just faint signs of melanin synthesis beginning at the cellular level. The gap between expectation and reality here isn't a product failure; it's a misunderstanding of how melanogenesis operates under synthetic alpha-melanocyte-stimulating hormone (α-MSH) analogs. Melanotan-1 (afamelanotide) doesn't work like a spray tan. It triggers your melanocytes to produce eumelanin through a multi-week cumulative process that requires both peptide administration and UV exposure to manifest visibly.
Our team has guided research participants through melanotropic peptide protocols for years. The single most common question we receive in week one isn't about dosage or reconstitution. It's 'Why don't I see anything yet?' This article covers exactly what melanotan-1 results after 1 week actually look like at the cellular level, what physiological markers indicate the peptide is working even when visible tanning hasn't occurred, and why the one-week checkpoint matters far more for protocol adjustment than it does for visual assessment.
What are melanotan-1 results after 1 week?
After one week of melanotan-1 administration at standard research doses (0.25–1mg subcutaneously per day), most subjects experience minimal to no visible skin darkening but demonstrate measurable increases in melanocyte activity via tyrosinase upregulation and basal eumelanin production. The peptide's 33-minute plasma half-life means steady-state receptor occupancy is achieved within 48–72 hours, establishing the hormonal foundation for tanning. But pigment deposition in the stratum corneum (the visible skin layer) requires 10–21 days of continuous stimulation plus UV exposure to become perceptible to the naked eye.
Direct Answer: The One-Week Reality Check
The Featured Snippet block gave you the mechanistic answer. Here's what that means in practice: if you're looking in the mirror on day seven expecting a tan, you're checking the wrong metric. Melanotan-1 results after 1 week aren't measured by skin tone. They're measured by absence of adverse effects, by the faint freckling or mole darkening that signals melanocyte activation, and by whether your dosing schedule is sustainable without nausea or injection site reactions that would derail the protocol before pigment accumulation begins. This article maps the biological timeline from peptide injection to visible tan, explains why UV exposure during week one matters more than the cumulative peptide dose, and identifies the three early indicators that predict whether your full-protocol results will meet expectations or require dose adjustment.
The Biological Timeline: What's Happening Beneath the Skin
Melanotan-1 binds to melanocortin-1 receptors (MC1R) on melanocyte cell membranes within minutes of subcutaneous administration. Receptor activation triggers a cascade through adenylyl cyclase and cAMP that upregulates tyrosinase. The rate-limiting enzyme in melanin synthesis. And shifts melanocyte output from pheomelanin (red-yellow pigment) to eumelanin (brown-black pigment). At one week, this enzymatic shift is fully established, but eumelanin particles are still accumulating in melanosomes (pigment organelles inside melanocytes) and haven't yet migrated to keratinocytes in the epidermis where they'd be visible. Research published in the British Journal of Dermatology demonstrated that tyrosinase activity peaks 48–96 hours after afamelanotide administration, but detectable increases in skin reflectance (measured by spectrophotometry) don't appear until day 10–14 in fair-skinned subjects.
The practical implication: melanotan-1 results after 1 week are invisible to the eye but measurable in labs. Subjects at this stage often notice existing moles or freckles darkening slightly. A direct marker that MC1R activation is occurring. While baseline skin tone remains unchanged. UV exposure during this window accelerates melanin transfer from melanocytes to keratinocytes, which is why controlled sun or UVB exposure starting in week one produces faster visible tanning than peptide alone. Without UV, the peptide establishes melanogenic capacity but doesn't fully express it visually until weeks 2–3.
Dosing Variables That Shape Week-One Outcomes
Standard research protocols for melanotan-1 use daily subcutaneous doses ranging from 0.25mg (ultra-conservative baseline) to 1mg (aggressive initiation). At 0.25mg daily, subjects reach steady-state plasma concentration by day three but experience minimal side effects and slower melanin accumulation. Visible tanning typically doesn't begin until week three without UV assistance. At 1mg daily, steady-state is achieved within 48 hours and side effects (nausea, facial flushing, appetite suppression) occur in 40–60% of subjects during the first week, but melanin synthesis accelerates proportionally. Subjects who tolerate this dose and incorporate UV exposure often see faint darkening by day 8–10.
The 33-minute half-life means melanotan-1 doesn't accumulate in tissues the way longer-acting analogs do. Each injection clears from plasma within six hours, so the one-week results you see (or don't see) reflect cumulative receptor activation, not peptide buildup. Doubling the dose doesn't double the tanning speed. It doubles the intensity of MC1R signaling, which increases tyrosinase expression but still requires time for melanin to be synthesized, packaged, and transported. Research teams using afamelanotide for erythropoietic protoporphyria found that meaningful photoprotection (a proxy for melanin density) required 10–14 days of daily dosing at 1mg regardless of baseline skin type.
Our experience: subjects who start at 0.5mg daily and titrate to 1mg by day four balance tolerability with melanogenic efficiency. Melanotan-1 results after 1 week at this schedule show minimal visible tanning but consistent early markers. Slight mole darkening, reduced sunburn threshold during controlled UV exposure, and absence of gastrointestinal side effects that would force dose reduction. The one-week checkpoint is about protocol validation, not aesthetic outcome.
Comparison Table: Melanotan-1 Week-One Outcomes by Dose and UV Exposure
The following table compares expected outcomes at the one-week mark across three dosing protocols with and without structured UV exposure.
| Dosing Protocol | Daily Dose | Visible Skin Darkening at Day 7 | Melanocyte Activity Markers | Side Effect Incidence | Professional Assessment |
|---|---|---|---|---|---|
| Conservative Baseline | 0.25mg SC daily | None. Baseline skin tone unchanged | Minimal mole darkening, no measurable change in skin reflectance | 5–10% experience mild nausea or flushing | Safest initiation protocol but slowest visible results. Requires 3+ weeks to see tanning even with UV |
| Standard Research Protocol | 0.5mg SC daily, no UV | Trace darkening in pre-existing freckles only | Moderate tyrosinase upregulation, slight reduction in sunburn threshold | 15–25% experience transient nausea or appetite suppression | Balanced approach. Establishes melanogenic foundation without overwhelming tolerability; visible tanning begins week 2–3 |
| Standard Protocol + UV | 0.5mg SC daily + 10–15 min UVB 3x/week | Faint overall darkening detectable under bright light | Strong tyrosinase activity, accelerated melanin transfer to keratinocytes | 20–30% experience side effects, mostly GI-related | Most efficient path to visible tanning. UV exposure compounds peptide effect and advances visible pigmentation by 7–10 days |
| Aggressive Initiation | 1mg SC daily | Minimal to faint darkening in fair-skinned subjects; slightly more in darker skin types | High tyrosinase expression, noticeable mole/freckle intensification | 40–60% experience moderate nausea, flushing, or fatigue in first 72 hours | Fastest melanin synthesis but highest dropout rate due to side effects. Only suitable for subjects with prior melanotropic peptide experience |
What If: Melanotan-1 Week-One Scenarios
What If I See No Changes at All After Seven Days?
Continue the protocol. Absence of visible tanning at one week is normal and expected. The peptide's effect on melanin synthesis is cumulative, not immediate. Verify that your reconstituted peptide was stored at 2–8°C and that injections are subcutaneous (not intramuscular, which reduces bioavailability). If existing moles or freckles haven't darkened even slightly by day 10, consider increasing the dose from 0.25mg to 0.5mg or adding controlled UV exposure three times weekly to stimulate melanin transfer.
What If My Moles Darkened but My Skin Tone Didn't Change?
This is the most common one-week outcome and indicates the peptide is working correctly. Mole darkening reflects localized melanocyte hyperactivity. These cells have higher MC1R density than surrounding skin and respond faster to α-MSH analogs. Baseline skin tone changes lag by 7–14 days because diffuse melanin deposition requires sustained tyrosinase activity across all epidermal melanocytes, not just pigmented lesions. Continue your current dose and add UV exposure if you haven't already. Pigment will follow.
What If I Experience Persistent Nausea in Week One?
Reduce the dose by 50% and split it into two daily injections (e.g., 0.25mg morning and evening instead of 0.5mg once daily). Nausea from melanotan-1 peaks 30–90 minutes post-injection and correlates with rapid MC1R activation in the hypothalamus, which modulates appetite and nausea signaling. Splitting the dose flattens the plasma concentration curve and reduces peak receptor occupancy without compromising cumulative melanogenic effect. If nausea persists beyond 72 hours at reduced dose, discontinue and consider restarting at 0.1mg daily. Some subjects require ultra-gradual titration.
The Unfiltered Truth About One-Week Expectations
Here's the honest answer: if you're using melanotan-1 because you want a tan for an event in two weeks, you're using the wrong peptide. Melanotan-1 results after 1 week are biologically significant but visually negligible. This is a slow-build protocol designed for sustained, natural-looking pigmentation over 4–8 weeks, not a crash tan. The peptide's design (a linear 13-amino-acid analog of α-MSH) prioritizes MC1R selectivity and safety over speed, which is why it's FDA-approved in some jurisdictions for photoprotection but not marketed as a cosmetic tanning agent. If you need visible color in under 10 days, melanotan-2 (a cyclic analog with 10× higher potency and broader melanocortin receptor binding) produces faster visual results. But also higher side effect rates and off-target effects that melanotan-1 avoids.
The one-week mark is a protocol checkpoint, not a results checkpoint. Subjects who see no visible tanning but tolerate the dose well and notice mole darkening are on track. Subjects who see no changes and experience persistent nausea or injection site reactions need dose adjustment. The expectation that melanotan-1 results after 1 week should include noticeable tan is rooted in melanotan-2 anecdotes, not afamelanotide pharmacology. These are different peptides with different timelines.
Melanotan-1 establishes the foundation in week one. The visible payoff comes in weeks 2–4 when cumulative melanin synthesis crosses the threshold of human perception. That's not a limitation. It's the reason this peptide produces durable, even pigmentation without the patchy rebound fading that faster-acting analogs often cause.
The peptides we supply at Real Peptides undergo amino-acid sequencing verification at every batch to confirm structural accuracy. Because one transposed amino acid in a 13-residue chain changes receptor binding affinity and renders the compound ineffective. If your melanotan-1 results after 1 week don't match the biological markers described here (no mole darkening, no side effects, no change in sunburn threshold), the issue is peptide integrity, not your physiology. Week one is when you learn whether your source delivered what they claimed.
"faqs": [
{
"question": "How long does it take to see visible tanning results from melanotan-1?",
"answer": "Visible tanning from melanotan-1 typically appears 10–21 days after initiating daily dosing at 0.5–1mg subcutaneously, depending on baseline skin type, UV exposure frequency, and cumulative peptide dose. Fair-skinned subjects (Fitzpatrick I–II) require closer to three weeks, while subjects with higher baseline melanin (Fitzpatrick III–IV) may see faint darkening by day 12–14. The peptide establishes melanogenic capacity in the first week, but pigment accumulation in visible skin layers lags behind enzymatic activation."
},
{
"question": "Can I speed up melanotan-1 results by increasing the dose in week one?",
"answer": "Increasing the dose from 0.5mg to 1mg daily does accelerate tyrosinase upregulation and melanin synthesis, but it also increases side effect incidence (nausea, flushing) by 25–35% and doesn't proportionally shorten the visible tanning timeline. You might see results 3–5 days earlier, not 10 days earlier. The rate-limiting step isn't peptide dose; it's the biological time required for melanin to be synthesized, packaged into melanosomes, transferred to keratinocytes, and migrate to the stratum corneum. UV exposure during week one has a larger impact on visible tanning speed than dose escalation."
},
{
"question": "What are the most common side effects of melanotan-1 in the first week?",
"answer": "Nausea (20–30% of subjects), facial flushing (15–25%), and appetite suppression (10–20%) are the most common side effects during the first week of melanotan-1 administration, peaking within 30–90 minutes of injection and resolving within 2–4 hours. These effects result from MC1R activation in the hypothalamus and autonomic nervous system, not from melanocyte activity itself. Side effects typically diminish by day 4–5 as receptor desensitization occurs, and splitting the daily dose into two smaller injections significantly reduces their intensity without compromising melanogenic efficacy."
},
{
"question": "Should I use UV exposure during the first week of melanotan-1?",
"answer": "Yes, controlled UV exposure (10–15 minutes of UVB three times weekly) during the first week accelerates visible tanning by stimulating melanin transfer from melanocytes to keratinocytes. A process the peptide initiates but UV exposure amplifies. Subjects who incorporate UV in week one typically see visible pigmentation 7–10 days earlier than those using peptide alone. However, UV should be dosed conservatively: melanotan-1 increases melanin synthesis but doesn't provide immediate photoprotection, so sunburn risk remains elevated until pigment accumulates in the epidermis (typically week 2–3)."
},
{
"question": "How do I know if melanotan-1 is working if I don't see tanning yet?",
"answer": "Three early markers indicate melanotan-1 is working even before visible tanning occurs: (1) slight darkening of existing moles or freckles by day 5–7, (2) reduced sunburn threshold during UV exposure (you tan slightly faster or burn slightly less than baseline), and (3) transient side effects (mild nausea or flushing) within 30–90 minutes of injection during the first 3–4 days. If none of these markers appear by day 10, verify peptide storage conditions (must be refrigerated at 2–8°C after reconstitution) and confirm subcutaneous injection technique."
},
{
"question": "What is the difference between melanotan-1 and melanotan-2 for tanning speed?",
"answer": "Melanotan-2 produces visible tanning 5–10 days faster than melanotan-1 because it's a cyclic peptide with 10× higher MC1R binding affinity and additional activity at MC3R and MC4R, which amplify melanogenesis but also cause broader side effects (spontaneous erections, increased libido, darker pigmentation of mucous membranes). Melanotan-1 (afamelanotide) is a linear peptide with selective MC1R activity, slower onset, and a safer side effect profile. It's the only melanotropic peptide approved for medical use in some jurisdictions. If speed is the priority and you tolerate off-target effects, melanotan-2 delivers faster results; if gradual, natural-looking pigmentation with minimal side effects is the goal, melanotan-1 is the appropriate choice."
},
{
"question": "Can melanotan-1 cause permanent skin darkening?",
"answer": "No, melanotan-1 does not cause permanent skin darkening. Pigmentation fades over 4–8 weeks after discontinuation as melanin-containing keratinocytes naturally shed and are replaced by new cells without continued melanotropic stimulation. Some subjects notice that previously faint freckles or moles remain slightly darker than baseline after cessation, but diffuse skin tone returns to baseline within two months. The peptide upregulates melanin synthesis while administered but doesn't alter the genetic regulation of melanocyte activity. Stopping the peptide stops the signal."
},
{
"question": "Is it safe to use melanotan-1 without a prescription?",
"answer": "Melanotan-1 (afamelanotide) is approved for prescription use in the European Union and Australia for erythropoietic protoporphyria, but it is not FDA-approved in the United States for any indication, including cosmetic tanning. Research-grade melanotan-1 purchased from non-medical suppliers is intended for laboratory use only, not human consumption. Self-administration carries risks including infection from non-sterile reconstitution, dosing errors, allergic reactions, and lack of medical oversight for contraindications (e.g., melanoma history, pregnancy). Anyone considering melanotropic peptide use should consult a licensed physician for safety screening and protocol guidance."
},
{
"question": "Does melanotan-1 protect against sunburn in the first week?",
"answer": "No, melanotan-1 does not provide meaningful photoprotection in the first week because melanin density in the epidermis hasn't increased enough to absorb UV radiation effectively. Tyrosinase upregulation and melanin synthesis begin within 48–72 hours, but pigment accumulation in the stratum corneum (where it blocks UV) requires 10–14 days. Subjects using melanotan-1 during week one still have near-baseline sunburn risk and should use sunscreen during UV exposure. Photoprotection improves progressively as visible tanning develops, typically reaching measurable efficacy by week 2–3."
},
{
"question": "Can I stop melanotan-1 after one week if I don't see results?",
"answer": "You can stop at any time, but discontinuing after one week means you'll never see the results the peptide was designed to produce. Visible tanning requires 10–21 days of continuous dosing. Melanotan-1 results after 1 week are intentionally minimal because the peptide establishes melanogenic infrastructure (tyrosinase upregulation, eumelanin synthesis pathway activation) before pigment becomes visible. Stopping at day seven is like planting a seed and digging it up before it sprouts. If you experienced no adverse effects and saw early markers like mole darkening, continuing the protocol for another 10–14 days is the only way to evaluate full efficacy."
}
]
}
References
Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.
- Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
- Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
- A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
- Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
- Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
- Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
- Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
- Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA